Pini Stefano, Radovanovic Dejan, Saad Marina, Gatti Marina, Danzo Fiammetta, Mondoni Michele, Aliberti Stefano, Centanni Stefano, Blasi Francesco, Chiumello Davide Alberto, Santus Pierachille
Division of Respiratory Diseases, ASST Fatebenefratelli-Sacco, Ospedale Luigi Sacco, Polo Universitario, 20157 Milano, Italy.
Department of Biomedical and Clinical Sciences (DIBIC), Università Degli Studi Di Milano, 20157 Milano, Italy.
J Clin Med. 2022 Dec 2;11(23):7186. doi: 10.3390/jcm11237186.
It is not known if the degrees of improvement in oxygenation obtained by CPAP can predict clinical outcomes in patients with COVID-19 pneumonia. This was a retrospective study conducted on patients with severe COVID-19 pneumonia treated with CPAP in three University hospitals in Milan, Italy, from March 2020 to March 2021. Arterial gas analysis was obtained before and 1 h after starting CPAP. CPAP failure included either death in the respiratory units while on CPAP or the need for intubation. Two hundred and eleven patients (mean age 64 years, 74% males) were included. Baseline median PaO2, PaO2/FiO2 ratio (P/F), and the alveolar-arterial (A-a) O2 gradient were 68 (57−83) mmHg, 129 (91−179) mmHg and 310 (177−559) mmHg, respectively. Forty-two (19.9%) patients died in the respiratory units and 51 (24.2%) were intubated. After starting CPAP, PaO2/FiO2 increased by 57 (12−113; p < 0.001) mmHg, and (A-a) O2 was reduced by 68 (−25−250; p < 0.001) mmHg. A substantial overlap of PaO2, P/F, and A-a gradient at baseline and during CPAP was observed in CPAP failures and successes; CPAP-associated improvements in oxygenation in both groups were similar. In conclusion, CPAP-associated improvements in oxygenation do not predict clinical outcomes in patients with severe COVID-19 pneumonia.
持续气道正压通气(CPAP)所带来的氧合改善程度能否预测新型冠状病毒肺炎(COVID-19肺炎)患者的临床结局尚不清楚。这是一项回顾性研究,研究对象为2020年3月至2021年3月在意大利米兰的三家大学医院接受CPAP治疗的重症COVID-19肺炎患者。在开始CPAP治疗前及治疗1小时后进行动脉血气分析。CPAP失败包括在使用CPAP期间呼吸单元内死亡或需要插管。共纳入211例患者(平均年龄64岁,74%为男性)。基线时,动脉血氧分压(PaO2)中位数、PaO2/吸入氧分数值(P/F)比值及肺泡-动脉血氧分压差(A-a)分别为68(57 - 83)mmHg、129(91 - 179)mmHg和310(177 - 559)mmHg。42例(19.9%)患者在呼吸单元内死亡,51例(24.2%)患者接受了插管。开始CPAP治疗后,PaO2/FiO2增加了57(12 - 113;p < 0.001)mmHg,(A-a)O2降低了68(-25 - 250;p < 0.001)mmHg。在CPAP治疗失败和成功的患者中,基线时及CPAP治疗期间的PaO2、P/F和A-a梯度存在大量重叠;两组中与CPAP相关的氧合改善相似。总之,与CPAP相关的氧合改善不能预测重症COVID-19肺炎患者的临床结局。